Noopept Reference

Reference summary

Russian-language clinical literature reports modest improvements in attention, memory, and emotional-volitional symptoms across cohorts with mild cognitive impairment, post-stroke cognitive symptoms, and asthenic states (Neznamov 2009, Amelin 2011, Kovalev 2008, Ostrovskaya 2007 review). Mechanistically, noopept and its primary active metabolite cycloprolylglycine are reported to enhance BDNF and NGF expression and modulate AMPA receptors in rodent models, framing the community nootropic positioning. Western peer-reviewed replication is thin, with effect sizes smaller than the Russian indication implies. No outcome-grade data outside the Russian regulatory context.

Regulatory and posture

Categories

Nootropic, Cognitive

Aliases

GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam

Evidence posture

human - Not FDA-approved in the US. Russian regulatory approval. Community nootropic framing extrapolates beyond the approved cognitive-impairment indication. Most clinical evidence is Russian-language, lower-quality methodologically, and not independently replicated in Western trials.

Regulatory status

No FDA-approved noopept drug label. Russian-approved for organic disorders of the central nervous system with cognitive impairment under the brand Noopept (originally developed at the Russian Academy of Medical Sciences by Ostrovskaya and collaborators). Sold internationally as a research-chemical or nootropic supplement; not a US dietary-supplement category match.

Content review status

research reference